Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC

CONCLUSION: Apatinib combined with DOS regimen is effective for patients with LAGC without significantly increasing adverse reactions. Meanwhile, tumor markers are reduced significantly. Besides, the Ro resection rate and the incidence of operative complications are obviously superior to the DOS neoadjuvant chemotherapy regimen alone.PMID:34912413 | PMC:PMC8613054 | DOI:10.12669/pjms.37.7.4265
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research